In the landscape of modern biochemical and biophysical research, the study of the peptide p53 has become a cornerstone for understanding cellular regulation and genome integrity. As a user deeply interested in the advancements of peptide chemistry, I have followed the evoluti P53 is able to conserving stability by preventing genome mutation. Notice: All peptides are only for research purposes, Not for clinical use. on of these synthetic tools, which are primarily utilized for laboratory-based exploration of protein-protein interactions.
The Biological Context of p53
The p53 protein, encoded by the TP53 gene, is widely recognized as a "guardian of the genome." It functions as a crucial tumor suppressor protein that guards the cell against various stress signals. In normal physiological conditions, the tran p53, also known as tumor protein 53 (TP53), is a transcription factor that regulates the cell cycle and hence functions as a tumor suppressor. scription factor p53 regulates the cell cycle by inducing growth arrest or apoptosis when DNA damage is detected. Because p53 acts as a tumor suppressor in many tumor types, it remains a primary focus for researchers investigating how to maintain genomic stability.
Synthetic Peptides and Their Research Applications
A synthetic peptide corresponding to the C-terminal r p53 egion of human p53 is frequently used as an immunogen to raise specific antibodies. These tools are essential for researchers who require a high-quality epitope peptide to validate antibody specificity in assays like ELISPOT or intracellular cytokine staining (ICS).
Furthermore, the development of specialized peptides has allowed for the deeper study of regulatory pathways. For instance, Mdm2 is a major negative regulator of the tumor suppressor p53 protein, and researchers often utilize a p53 (17-26) peptide, which is derived from the P53 MDM2 binding domain, to study this interaction. With a dissociation constant (Kd) of approximately 50 nM for MDM2, this specific sequence is a standard tool in structural biology.
Advancements in Peptide Engineering
The field has moved beyond simple sequences into complex molecular design:
* D-peptide antagonists: These are developed as a class of p53 activators to target the MDM2 interaction.
* Stapled Peptides and Macrocycles: Compounds like ALRN6924 represent the cutting edge of research, designed to inhibit the interaction between p53 and its negative regulators (MDM2/MDMX).
* Senolytic Peptides: Recent studies have highlighted how FOXO4-DRI is a senolytic peptide that targets p53, offering new avenues for studying cellular senescence.
* Stabilizing Peptides: Sequences like the nine-residue CDB3 peptide were engineered to bind the core domain of p53, stabilizing it against denaturation.
Research Considerations and Safety
It is important to emphasize that these materials are strictly for research purposes. Whether discussing p53-derived peptides from the MDM-2 binding domain or investigating how iASPP is an evolutionarily conserved p53 inhibitor, all laboratory work must adhere to rigorous safety protocols.
Because the TP53 gene provides instructions for p53 (17-26) is a peptide derived from the P53 MDM2 binding domain, with a Kd of 50 nM for MDM2. p53 (17-26) causes cell lysis by damaging cancer cells and making a protein that essentially serves as a major p53 (17-26) is a peptide derived from the P53 MDM2 binding domain, with a Kd of 50 nM for MDM2. p53 (17-26) causes cell lysis by damaging cancer cells and barrier against malignant transformation, understanding its mechanics is vital. P53 is able to conserve stability by preventing genome mutation, and as such, it remains the most frequently studied protein in molecular oncology. Whether you are working with an overlapping peptide pool or a specific p53 fragment, the goal remains the same: to elucidate the complex biochemical pathways that protect cellular integrity.
*Disclaimer: This content is for educational and research purposes only. It does not provid Pool of 96 peptides derived from a peptide scan through Cellular tumor antigen p53 (Swiss-Prot ID: P04637) of Human. e medical, clinical, or therapeutic advice.*